Announcements Trials
Browse Landscape

Status

No longer available 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 27Expanded_access 2

Sponsor

Cancer Type

Breast 2

Conditions

Triple Negative Breast Neoplasms 2

Interventions

veliparib 2tucatinib 2leronlimab 2abemaciclib 2Trastuzumab 2Capecitabine 2Alpelisib 2zenocutuzumab 1selpercatinib 1sacituzumab govitecan 1ribociclib 1pertuzumab 1pegilodecakin 1palbociclib 1margetuximab 1iniparib 1glembatumumab vedotin 1gedatolisib 1eribulin 1Vinorelbine 1Proton Pump Inhibitors 1Letrozole 1Lapatinib 1Hydrocortisone 1Everolimus 1Cisplatin 1Ado-Trastuzumab Emtansine 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × veliparib × Breast × Clear all
NCT03123211 2022-05-24

Expanded Access to Veliparib

AbbVie

No longer available
Breast

Triple Negative Breast Neoplasms

NCT02985658 2021-07-21

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

University of Washington

No longer available
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡